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Nanobodies mapped 
to cross‑reactive and divergent 
epitopes on A(H7N9) influenza 
hemagglutinin using yeast display
Tiziano Gaiotto1, Walter Ramage1, Christina Ball1, Paul Risley1, George W. Carnell3,4, 
Nigel Temperton3, Othmar G. Engelhardt2 & Simon E. Hufton1*
Influenza H7N9 virus continues to cause infections in humans and represents a significant pandemic 
risk. During the most recent 5th epidemic wave in 2016/17 two distinct lineages with increased human 
infections and wider geographical spread emerged. In preparation for any future adaptations, broadly 
reactive antibodies against H7N9 are required for surveillance, therapy and prophylaxis. In this 
study we have isolated a panel of nanobodies (Nbs) with broad reactivity across H7 influenza strains, 
including H7N9 strains between 2013 and 2017. We also describe Nbs capable of distinguishing 
between the most recent high and low pathogenicity Yangtze River Delta lineage H7N9 strains. 
Nanobodies were classified into 5 distinct groups based on their epitope footprint determined using 
yeast display and mutational scanning. The epitope footprint of Nbs capable of distinguishing high 
pathogenic (HP) A/Guangdong/17SF003/2016 from low pathogenic (LP) A/Hong Kong/125/2017 
(H7N9) were correlated to natural sequence divergence in the head domain at lysine 164. Several Nbs 
binding to the head domain were capable of viral neutralisation. The potency of one nanobody NB7‑
14 could be increased over 1000‑fold to 113 pM by linking two Nbs together. Nbs specific for distinct 
epitopes on H7N9 may be useful for surveillance or therapy in human or veterinary settings.
Influenza A virus (IAV) remains a persistent threat to public health resulting in 200,000–500,000 deaths world-
wide annually which can be even higher in a pandemic  emergency1. In the last century, four pandemics have led 
to many human deaths caused by three subtypes, H1N1 in 1918 and 2009, H2N2 in 1957 and H3N2 in  19682, 3. 
In more recent years a number of avian influenza viruses, for example, H5N1 and H7N9, have crossed into the 
human population, but fortunately these zoonotic outbreaks have not yet become pandemics due to their low 
human-to-human  transmissibility4. However, a more recent outbreak of H7N9 in China in 2016–2017 resulted 
in substantial geographical spread with the emergence of H7N9 strains carrying a polybasic cleavage site which 
can facilitate systemic spread beyond the  lungs5, 6. As such, H7N9 may be considered a serious pandemic threat 
and there is a pressing need to prepare for robust global responses which can be rapidly implemented should this 
virus ever become highly transmissible within the human population. Vaccines remain the main prophylactic 
treatment option and in March 2017 the WHO recommended new candidate vaccine viruses be made from the 
Yangtze River Delta lineage of the low pathogenic A/Hong Kong/125/2017 (H7N9) [(LP)HK/2017(H7N9)] and 
the high pathogenic A/Guangdong/17SF003/2016 (H7N9) [(HP)GD/2016(H7N9)] viruses, which are currently 
being evaluated in clinical  trials7, 8.
Although vaccines remain the mainstay of infection control for influenza, their timely implementation, poor 
immunogenicity in certain patient groups and limited worldwide production capacity remain a considerable 
technical challenge. Anti-viral drugs are available although resistant viral strains are  emerging9. Passive transfer 
of serum from convalescent patients is an option which was deployed, with some success, in the 1918  pandemic10 
and more recently to treat a severely ill H5N1  patient11. However, this approach cannot be implemented on a 
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global scale due to limited supply, high risk of toxicity, uncertain dosing, and difficulties in administration. A 
more promising approach is passive immunotherapy with recombinant monoclonal antibodies with broad reac-
tivity against H7N9 which can be manufactured with consistent quality, stockpiled, and delivered immediately 
in a pandemic  emergency12–14.
As a typical member of the IAV family, H7N9 is classified through the major viral envelope glycoproteins, 
hemagglutinin (HA) and neuraminidase (NA). HA is a homo-trimeric molecule with each monomer consist-
ing of two chains, HA1 and HA2 which fold into a structure comprising a highly variable globular head and a 
more conserved proximal stem  domain15. HA mediates virus entry into host cells through the receptor binding 
site on the globular head interacting with sialic acid receptors on the cell surface. This in turn leads to virus 
internalisation, and then membrane fusion mediated by the HA stem  region15. The pre-dominant host immune 
response is directed against the  HA16 and this selective pressure drives the continuous antigenic changes in 
 HA17. The high mutation rate and transmissibility means the discovery of new therapeutics is an active area 
of  research14 and a number of broad spectrum human monoclonal antibodies (mAbs) specific for H7N9 have 
been described including  CT14918, H7.16719,  M82620,  HNIgGD521  HNIgGA622 L4A-1423 and  P52EO324. These 
monoclonal antibodies have been identified from human donors after either natural IAV infection or H7 subunit 
 vaccination7, 19 and unusually have limited somatic hypermutation. This suggests that they are the result of an 
early and immediate response to H7N9, likely biased by previous immune history of exposure to  influenza19, 23. 
In addition, recent reports have suggested that an effective protective immune response to H7N9 infection is 
extremely rare in  humans23. Alternative approaches to generating mAbs to H7N9 which have been extensively 
optimised, could be expected to yield molecules of higher affinity and to potentially different epitopes to those 
targeted by the human immune system.
Although HA is continually changing, there are certain parts of the HA that are highly conserved, principally 
because they are essential for the infection process. Two functionally conserved sites lie within the receptor 
binding site and the HA stem which are required for viral uptake and membrane fusion,  respectively15. Several 
cross-reactive human antibodies have been isolated against the highly conserved HA  stem25, 26 or the receptor 
binding site of the head  domain27. In several cases the route to cross-reactivity is achieved through using only 
their heavy chain for binding or through using a smaller binding  footprint25–27. Conceptually a much smaller 
antibody epitope footprint may give a variable HA antigen less opportunities to escape binding and in effect there 
will need to be a mutational ‘bullseye’ for the virus to evade binding. Guided by these observations we have used 
nanobodies (Nbs) from alpacas as a potential route to cross-reactive  antibodies28–30 as they are naturally devoid 
of a paired light chain and have a propensity to bind small pockets on protein  surfaces31. In addition, given that 
camelid species are not thought to represent a zoonotic reservoir for influenza A, they may not be subject to the 
same immune constraints as human donors with prior exposure to  IAV32. The unique properties of Nbs which 
also include small size, simple engineering into multi-domain antibodies and high stability are being exploited 
for a wide range of applications in biotechnology including diagnostics and  immunotherapy31, 33, with the first 
nanobody, Caplicizumab, having been approved for the treatment of a blood clotting disorder in August  201834.
In this study we have isolated Nbs with both cross-reactive and strain specific binding to the prototype 
low pathogenicity (LP) and high pathogenicity (HP) A(H7N9) strains which have emerged in the most recent 
5th epidemic wave. We correlate their specificity and functional activity with their epitopes which have been 
mapped using yeast display and mutational scanning. This technique allows high throughput epitope mapping 
and identifies mutations that directly interfere with antibody binding. Their potential as tools for surveillance 
or emergency therapeutics in both human and veterinary applications is discussed.
Results
Isolation and characterisation of nanobodies specific for H7 hemagglutinin (HA). A juvenile 
male alpaca was immunised with purified recombinant H7-HA (Fig. 1a) from the human H7 strain A(H7N7) 
HA (A/Netherlands/219/2003) and an antigen specific serological immune response was seen in both ELISA 
and viral micro-neutralisation assays (Fig. 1b,c). After a third booster injection a phage displayed nanobody 
library of 9.6 × 107 was constructed using purified peripheral blood mononuclear cells. Two phage display library 
selection strategies were used, (i) sequential rounds of selection on the same antigen to yield all Nbs specific for 
H7-HA (H7N9 or H7N7) or (ii) alternating selections between H7-HA and H3-HA to bias towards cross-subtype 
reactive Nbs. Primary screening involved picking random clones and testing for binding to recombinant HA and 
whole virus inactivated antigen reagents of subtypes H3 and H7 sub-types as non-purified Nbs. Clones that were 
positive in ELISA were then sequenced and grouped into clonally related families based on their VHH-CDR3 
sequences (Table 1). Nbs with homologous VHH-CDR3 sequences of identical length were taken as belonging to 
the same clonal family and predicted to recognise the same or closely related epitopes. Several families of nano-
bodies containing homologous VHH-CDR3 sequences were identified which were likely derived from the same 
B cell lineage (Table 1). Nbs were purified and screened in ELISA on a panel of whole virus H7 antigen prepara-
tions to assess the breadth of cross-reactivity across both avian and human H7 strains from 2000 up to the most 
recent 5th epidemic wave of H7N9 in 2016–17. Most Nbs were capable of homo-subtypic cross-reactivity against 
influenza H7 strains, including H7N9 strains from 2013 to 2017 such as (HP) A/Guangdong/17SF003/2016 
(H7N9) [(HP)GD/2016] and (LP) A/Hong Kong/125/2016 (H7N9) [(LP)HK/2017] Yangtze River Delta Line-
age strains. We also identified a subgroup of Nbs (NB7-03, NB7-10 and NB7-13) which had lost binding to the 
most recent (HP)GD/2016 H7N9 strain. Nanobodies NB37X-01 – 04 were a distinct group with hetero-subtypic 
cross-reactive binding which extended to include the group 2 strain A/Texas/50/2012 (H3N2).
We used yeast display to identify further hetero-subtypic H3/H7 cross-reactive Nbs that may have been 
missed using conventional phage display library screening. This technology has advantages over phage display as 
highly controlled selection strategies are possible where each individual yeast cell can be quantitatively selected 
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for multiple parameters using flow cytometric cell  sorting28, 35, 36. The VHH genes from the immunised alpaca 
were cloned into a yeast display vector (Fig. 1a) and the resulting library sorted for H7-HA binding and then 
subsequently with H3-HA (Fig. S1). By co-labelling with an anti-SV5 epitope tag, antibody antigen binding 
could be normalised to display level. Cross-reactive Nbs were predicted to bind to more conserved epitopes 
in the HA stem  region28, so we performed a third round of ‘negative’ sorting using purified recombinant HA1 
head domain, selecting cells displaying Nbs that do not bind the head domain (Fig. S1). Sequence analysis of 
randomly picked yeast clones from this epitope guided yeast library selection strategy gave exclusively H3/H7 
cross-reactive nanobodies demonstrating the precision possible using cell sorting of yeast displayed libraries. 
In addition, two new Nbs (NB37X-05 and NB37X-06) with unique CDR3 sequence were identified which were 
not recovered using phage display.
The final panel of 22 Nbs was then screened for neutralisation activity using pseudotyped viruses displaying 
the HA of A/Shanghai/02/2013 (H7N9) (Table 1). Several Nbs were neutralising with the most potent group 
being NB7-01, NB7-09, NB7-11 and NB7-14 which all belonged to the same clonal lineage with homologous 
VHH-CDR3 sequences of identical length. One of the advantages of Nbs over conventional mAbs is that they 
can be easily reformatted into multi-domain antibodies as all antigen binding activity is confined to a single 
domain. Linking Nbs together has been shown to significantly increase their potency through  avidity29, 37 and 
we investigated whether similar increases in potency were possible with the lead nanobody NB7-14. Bivalent 
versions of NB7-14 were produced by fusing two identical binding domains separated by a thirty amino acid 
glycine linker and saw an increase in potency of more than 3 orders of magnitude to an IC50 (half maximal 
inhibitory concentration) of 113 pM (Fig. 2). Previous studies have shown that a bivalent nanobody specific for 
the head domain of H5N1 had substantially increased potency compared to the monovalent counterpart in both 
in vitro neutralisation assays and a mouse challenge  model38. Our findings agree with these studies and suggest 
bivalent NB7-14 has improved potency through enhanced avidity and cross-linking of HA through either inter- 
or intra- molecular interactions.
Epitope mapping of H7‑HA specific nanobodies. To group Nbs as either head or stem specific we 
evaluated binding to purified recombinant HA1 head domain and full length HA0 protein using surface plas-
Figure 1.  Isolation of H7-HA specific nanobodies. (a) The number of clones screened and the number of H7 
or H3/H7 specific Nbs identified are shown from either phage display or yeast display library selection (Fig 
S1). (b) Serological immune response in immunised alpaca to A/Anhui/01/2013 (H7N9). Samples were taken 
pre-immunisation and after each of three boosts. (c) Serological neutralising immune response in immunised 
alpacas using micro-neutralisation assays of A/Anhui/01/2013 (H7N9) NIBRG-268. A positive control sheep 
serum specific for the reverse genetics virus was used as a positive control.
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mon resonance and single cycle  kinetics39. H7-specific Nbs (NB7-01 to 17) showed high affinity binding to both 
the HA1 domain and full length HA0 (Table 2) indicating that their epitopes lie in the globular head domain. 
Several Nbs had affinities less than 1 nM as a monovalent binding affinity constant (Fig. S2) and binding affinity 
was retained across all H7 strains tested including the most recent A/HongKong/125/2017 (H7N9). The hetero-
subtypic cross-reactive nanobodies NB37X-01 to 06 did not show any binding to the head domain, however, 
they showed some degree of binding to full length HA0, but the data could not be fitted using a 1:1 model. This 
Table 1.  Nanobody sequence, specificity and neutralisation activity. VHH-CDR3 sequences and family 
grouping of related sequences. ELISA is given as the average OD450nm reading of two wells coated with 
whole virus antigen and Nbs added at a single concentration of 5 µg/ml. – indicates OD450 < 0.1 and 
represents no binding. Inactivated whole virus antigens used TX/2012(H3N2) [A/Texas/50/2012 (H3N2)], 
M/N/2000(H7N3) [A/Mallard/Netherlands/12/2000], NY/2003 (H7N2) [A/New York/107/2003], AN/2013 
(H7N9) [A/Anhui/01/2013], GD/2016 (H7N9) [A/Guangdong/17SF003/2016], HK/2017 (H7N9) [A/
HongKong/125/2017]. Pseudotype based micro-neutralisation assays using A/Texas/50/2012 (H3) and 
A/Shanghai/02/2013 (H7) HA bearing pseudoviruses. += 500-3000 nM, ++ < 500 nM, +++< 100 nM, 
++++  < 50 nM, +++++< 10 nM, - no neutralisation.
Nb



















NB7-01 ALARSVDRL-TYDY (1) - 2.83 2.53 2.26 2.59 1.94 - ++++





- 2.04 - 1.30 - 0.52 - +++
NB7-04 AASPIPDLRDYDY (4) - 0.84 1.62 0.71 3.37 0.31 -  +
NB7-05 NVWIQFHNY - 0.17 - 0.19 - 0.38 - -
NB7-07 AFGATLYG-VRRDEYAY - 1.99 1.96 1.46 2.73 0.48 - +++
NB7-08 AADRYSGPYDL-GTISPRQDHYDV - 0.91 1.52 0.91 2.65 2.05 - -





- 1.64 - 1.20 - 2.30 - +++
NB7-11 AVARSVDR-LEYDY (1) - 1.03 1.23 1.24 3.12 2.53 - ++++
NB7-12 HASPRDVLVDYD (2) - 1.73 2.57 1.78 3.28 2.47 - ++++
NB7-13 AADFLTLQDM-CVLSPITRYRS (3) - 1.14 - 0.72 - 2.37 - +++
NB7-14 ALARSVDRL-TYDY (1) - 2.67 2.75 2.08 3.00 2.57 - +++++ 
NB7-15 AAG RTY CGLR-GYEYDY - 2.23 0.20 1.92 2.97 2.56 - ++++ 
NB7-16 AASPIPTLRDYDY (4) - 1.44 1.71 1.08 2.86 2.42 - +++
NB7-17 AASPRRLMCV-PAEFDLYY - 2.44 2.57 1.97 2.39 2.07 - ++++ 










0.12 - - - 0.34 - - -





0.40 0.14 0.17 0.26 0.31 2.32 - -
NB37X-06 AADRVDYPGGG ATC RTSSAAYDH 0.26 - 0.20 0.20 0.36 2.55 - -
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suggests that this group of H3/H7 cross-reactive nanobodies bind to epitopes outside of the head domain and 
likely to epitopes within the HA stem region.
For precise epitope localisation we used yeast surface display coupled with mutational scanning which we 
have described  previously28. The HA0 precursor gene of hemagglutinin A/Netherlands/219/2003 (H7N7) was 
sub-cloned into a yeast display vector in frame with an SV5 epitope tag. The use of a C-terminal epitope tag 
allows the detection and sorting of correctly folded HA displayed on the yeast surface independently of Nb 
Figure 2.  Comparison of neutralisation of H7N9 by monovalent and bivalent NB7-14. Pseudotype micro-
neutralisation assay performed using influenza A/Shanghai/02/2013 (H7) HA bearing pseudovirus and mono- 
and bivalent nanobody NB7-14. Percentage neutralisation is plotted against molar concentration of NB7-14 
in two different formats (nM). IC50 for monovalent NB7-14 (17 nM) and for bivalent NB7-14 (130 pM). 
Neutralisation of A/Texas/50/2012 (H3N2) was negative (data not shown).
Table 2.  Characterisation of nanobody binding affinity and head/stem specificity. 1 HA1 is purified 
hemagglutinin head domain. 2 HA0 is purified full length hemagglutinin. # binding seen but could not be fitted 
using 1:1 fitting model. - no binding could be seen.
Nanobody
Affinity (KD)











NB7-01 -  < 0.1 nM 4.80 nM 0.83 nM
NB7-02 - 6.19 nM 17.3 nM 6.24 nM
NB7-03 - 24.80 nM 35.70 nM 27.45 nM
NB7-04 - 8.74 nM 26.9 nM 10.79 nM
NB7-05 - 140 nM 6.96 nM  > 1 µM
NB7-07 - 0.81 nM 4.31 nM 0.78 nM
NB7-08 - 1.26 nM 2.22 nM 15.48 nM
NB7-09 -  < 0.1 nM 0.38 nM 0.93 nM
NB7-10 - 24.0 nM 21.6 nM 46.24 nM
NB7-11 - 4.60 nM 58.8 nM 18.74 nM
NB7-12 - 1.05 nM 1.50 nM 3.72 nM
NB7-13 - > 1 µm – > 1 µm
NB7-14 - < 0.1 nM 2.36 nM 0.41 nM
NB7-15 - 0.42 nM 1.24 nM 0.77 nM
NB7-16 - 1.63 nM 9.98 nM 4.95 nM
NB7-17 - 1.43 nM 1.30 nM 2.40 nM
NB37X-01 # - # -
NB37X-02 # - # -
NB37X-03 # - # -
NB37X-04 # - # -
NB37X-05 # - # -
NB37X-06 # - # -
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binding using flow cytometry (Fig. S3). All Nbs showed binding to yeast cells displaying H7-HA0 suggesting 
that the epitopes could be located.
Subsequently, a library of H7-HA0 mutants was generated by error-prone PCR using low-error rate mutagen-
esis. Initially the library was selected by incubating with NB7-14 and NB7-08 separately, and mutants which 
completely lost binding were recovered through two sequential rounds of ‘negative’ flow cytometric cell sorting. 
As allosteric mutations distant from the actual physical binding footprint could, in principal, lead to loss of bind-
ing, we performed a third round of ‘positive’ sorting with a non-competing antibody targeting the stem domain 
(Fig. 3a). This selection step focuses the recovery of mutations which lie within the physical epitope footprint 
of NB7-08 and NB7-14 and biases against HA mutations that may have an indirect effect on binding through 
structural disruption distant from the site of physical interaction. Following selection, random clones (n = 30) 
were picked, sequenced and aligned to wild-type HA0 to identify HA mutations which were enriched compared 
to the unselected library. These selectively enriched mutations were predicted to form part of the physical epitope 
footprint and were chosen for further testing. Clones with mutations introducing/replacing cysteine or proline 
residues were discarded as they were predicted to have indirect or pleiotropic effects on  binding28. Only HA 
mutations which were shown to interfere with Nb binding without affecting HA display level were classified as 
epitope residues. Selection for loss of binding to NB7-08 identified mutations D67G, D67V, L70S and D246N 
located in the HA1 domain, (Fig. S4). D67 was mutated to both glycine and valine, reflecting its importance 
within the epitope of NB7-08. For NB7-14, HA-D67G was also selected, however HA-S135A mutation was also 
enriched (Fig. 3b,c) reflecting NB7-14 has a distinct but overlapping epitope footprint with NB7-08.
Each individual HA mutation was subsequently tested for binding to the complete panel of H7-HA specific 
Nbs (Fig. 3b,c) to allow grouping Nbs with overlapping epitopes. Although 11/16 Nbs lost binding due to a 
mutation at D67 and could be classed as broadly belonging to a single epitope group (Gp1) it was clear that 
epitope groups could be further de-lineated based on the individual mutations capable of disrupting binding.
The remaining Nbs (NB7-03, NB7-05, NB7-10, NB7-13 and NB7-15) that were not affected by the D67 
mutations required further HA library selections to identify their respective epitopes. In selections with NB7-15, 
two separate mutations at residue 71 (E71G and E71V) were selected and placed NB7-15 in a separate epitope 
group (Gp2). Selections with NB7-03 gave mutations E111V, R163G and K164E, again placing it in a further 
separate epitope group, Gp3 (Fig. 3b,c). Residue E111 was identified as particularly important as it was recovered 
multiple times mutated to different residues E111(G/D/K/R). Since binding of NB7-05 was not affected by any 
of the previously selected HA mutations, additional selections were done and R211S and R220S were shown to 
specifically disrupt its binding, placing it in epitope group 4 (Gp4) (Fig. 3b,c).
All selected mutations were finally tested against the whole panel of Nbs which allowed the Nbs to be placed 
into 4 distinct epitope binding groups (Gp1, Gp2, Gp3, Gp4) with Gp 1 being divided into subgroups (Gp1a, 
Gp1b, Gp1c, Gp1d )(Fig. 3b,c) based on different combinations of mutations with D67. All mutations were 
mapped onto the structure of H7-HA and could be seen to be surface exposed residues, which suggests a direct 
involvement in Nb binding rather than a more general structural disruption (Fig. 5). Nbs belonging to the same 
epitope grouping in several cases had unique VHH CDR3 sequences reflecting their unique paratopes. This is an 
important consideration as, although they may have overlapping epitopes, they might present a different genetic 
barrier to a constantly changing influenza HA antigen.
The cross-reactive Nbs NB37X-01 and NB37X-05 were shown to bind only full length H7-HA0 with the 
absence of binding to the H3-HA1 head domain (Fig. S3) suggesting the epitope(s) lie(s) within the more 
conserved stem region. The H7-HA0 library was selected separately with NB37X-01 and -05, and identified 
five residues (M102, E103, E114, M115, Y119) that specifically interfered with Nb binding (Fig. 4a,b) which all 
mapped to the HA stem. None of the HA stem mutations had any effect on the binding of the Nbs (NB7-01 to 
17) which have epitopes in the head domain. In addition, both M102 and M115 were mutated to more than one 
residue reflecting the importance of these residues. The entire panel of cross-reactive Nbs showed loss of binding 
to all 5 mutants with the exceptions of NB37X-04 and NB37X-06, which retained binding to the HA2-E114V 
mutation. This suggests they have a common physical footprint within the stem domain (Fig. 5). However, they 
could be placed in two epitope subgroups (Gp5a and Gp5b) based on the differential effect of the HA2-E114V 
mutation. This cross-reactive epitope sits within the HA2 helix of the stem which has a crucial role in influenza 
infection by mediating a large conformational change in the acidified endosomal compartment to initiate mem-
brane fusion. We evaluated if binding of the heterosubtypic H3/H7 cross-reactive stem binding Nbs could be 
affected by this conformational change by mimicking it in vitro through exposure of HA to low pH. We used a 
yeast display based sandwich assay where we sub-cloned the H7-specific antibody NB7-14 into the yeast display 
vector to bind HA via the head domain and treated HA with different pH buffers followed by probing with the 
putative stem binding Nbs (Fig. 4c). All cross-reactive Nbs (NB37X-01 to 06) showed a substantial increase 
in binding upon low-pH treatments whereas the head binder NB7-04 bound HA at both pH 4.8 and pH 8.0 
equally well (Fig. 4c). As NB7-04 and NB7-14 share an overlapping epitope footprint in the head domain the 
binding seen with the head specific nanobody indicates that trimeric HA is being detected in this assay format. 
This confirms that the cross-reactive Nbs bind to the HA stem region and suggests that they have preferential 
binding to the low pH conformation.
Correlation of nanobodies belong to epitope Gp3 to natural sequence divergence. Epitope 
group Gp3, comprising NB7-03, NB7-10 and NB7-13, were unique as these Nbs did not show any binding to 
the most recent highly pathogenic avian influenza A(H7N9) strain A/Guangdong/17SF003/2016 and the human 
H7N2 strain (A/NewYork/107/2003). The epitope footprint of these Nbs comprises E111, R163 and K164, and 
sequence comparison of the strains tested in ELISA identified this as a region of natural sequence divergence 
(Fig. 6) These two influenza strains have a naturally occurring substitution at K164 to either a glutamate (E) or 
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Figure 3.  Epitope footprints of H7-HA specific nanobodies. (a) Example selection campaign for NB7-14 showing two rounds of 
‘negative’ selection followed by a third round of ‘positive’ selection. (b) Flow cytometry histograms (FlowJo 10.4 software) showing Nb 
binding to yeast displayed wild-type H7-HA0 (A/Netherlands/219/2003) and binding of NB7-14, NB7-08, NB7-15, NB7-03, NB7-05 to 
yeast displayed HA carrying the mutations as indicated. (c) Binding activity to a panel of yeast displayed H7-HA0 mutants with residue 
numbering relative to HA1 domain. Each Nb is grouped by binding profile. Blue cells indicate the specific Nb used for HA library 
selections. Commercial H7-HA specific antibody MIA-H7-334 is included as positive control and retains binding to all mutants. Relative 
Nb binding to each yeast displayed HA mutant was calculated by dividing the MFI (mean fluorescence intensity) of Nb-mutant HA 
pair with the value for wild type H7-HA incubation and the resulting ratio normalised to percentage values. Binding was categorized as 
follows, ≤ 15% no binding (red), between 15 and 40% intermediate binding (orange) and ≥ 40% positive binding (green).
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asparagine (N) (Fig. 6). Of particular interest was our being able to select the naturally occurring HA1-K164E 
substitution from a yeast displayed error prone PCR HA library. This artificially generated mutation correlated 
with a naturally occurring sequence difference between the prototype low pathogenic and high pathogenic 
strains of A(H7N9)40. This suggests that yeast display may be used as a tool to investigate the evolution of the HA 
molecule under different selective pressures without the need to use live virus and high containment facilities.
Figure 4.  Epitope footprint of H3/H7 cross-reactive nanobodies. (a) Flow cytometry histograms (FlowJo 10.4 
software) showing NB37X-01 and NB37X-05 binding to displayed wild type H7-HA0 and mutants selected (b) 
Nb binding activity to a panel of yeast displayed HA0 mutants. Residue numbering is relative to HA2 domain. 
The Nbs used for epitope mapping are highlighted in blue. Commercial antibody MIA-H7-334 is included 
as positive control and retains binding to all mutants. Relative binding of Nbs to each displayed mutant were 
categorized as follows: ≤ 15% no binding (red), between 15 and 40% intermediate binding (orange) and ≥ 40% 
strong binding (green). *Represents retention of binding to the HA1 head domain carrying a non-relevant 
mutation HA1-S135A (c) yeast cells displaying the head specific Nb NB7-14 were incubated with HA treated 
with low and neutral pH and binding of the stem specific Nbs NB37X-01 and NB37X-05 was detected as mean 
fluorescent intensity (MFI). NB7-04 was a non-competing head specific nanobody control.
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Discussion
To date there have been 5 epidemic waves of zoonotic infections of influenza A(H7N9) with up to 1568 reported 
cases of human infection (https ://www.who.int/influ enza/vacci nes/virus /20190 9_zoono tic_vacci nevir usupd ate.
pdf?ua=1) with a 40% fatality rate. During the 5th wave in 2016–17, the emergence of highly pathogenic avian 
influenza (HP) A(H7N9) raised significant concerns as unlike (LP) A(H7N9) it maintained the capacity to infect 
via both human and avian  receptors41, 42. In preparation for any further adaptations in H7N9 which could threaten 
a pandemic, vaccines, anti-viral drugs and monoclonal antibodies which can be used for control, surveillance 
and as emergency prophylactics are essential.
In this study we have isolated a panel of homo-subtypic H7 and hetero-subtypic H3/H7 cross-reactive Nbs. 
We demonstrate that alpacas immunised with a single H7 strain can yield Nbs with broad reactivity which 
can maintain binding and resistance to natural antigenic changes over a minimum of 17 years. We have also 
isolated Nbs which can distinguish between the most recent high pathogenicity avian influenza strain (HP) A/
Guangdong/17SF003/2016 and the low pathogenicity (LP) A/Hong King/125/2017 (Fig. 6). In many cases Nbs 
were very high affinity (less than 1 nM) reflecting extensive somatic hypermutation and optimisation by the 
alpaca immune system. This could be expected as to date alpaca’s are not thought to be a reservoir for IAV so 
should not have any prior immune history of exposure to group 2  viruses32. This is in contrast to many of the 
human monoclonal antibodies to H7N9 where very few somatic mutations are seen, suggesting the antibodies 
are derived from an early, essentially germline response, to the  virus7, 19.
To understand the functional significance of Nb cross-reactivity we have mapped their epitopes using yeast 
display and mutational scanning. This approach is not limited by the need to maintain infection as is the case 
with conventional viral escape assays which uses live influenza virus and high containment  facilities28. Using 
yeast display we are able to do a comprehensive mutational scan which encompasses both physical and func-
tional epitope footprints, which are only limited by the need to preserve a folded, conformationally correct HA 
molecule anchored to the yeast cell  surface28. Our sequential analysis of selection on individual Nbs to identify 
HA mutations which disrupt binding, followed by screening on the wider Nb panel, has allowed the Nbs to be 
placed into 5 major epitope groups (Gp1, Gp2, Gp3, Gp4 and Gp5). Epitope group Gp1 was the largest group 
with 11 different Nbs which could be further divided into 4 sub-groups which, although sharing D67 as a key 
epitope residue (Fig. 5), showed clear distinctions in their physical footprint. This is consistent with each Nb 
having unique paratopes determined principally by their VHH-CDR3 sequence and being derived from different 
ancestor B cells. It is interesting to speculate that this information may be used to predict different trajectories for 
HA escape from binding and be useful in choosing optimum combinations of antibodies. This is an important 
consideration in designing multi-domain antibodies or antibody cocktails for therapeutic applications where 
targeting multiple epitopes has the potential to reduce the risks of viral escape. The generation of multi-domain 
antibodies using conventional monoclonal antibodies is complex, principally due to the antigen combining site 
requiring the stable pairing of two separate light chain and heavy chain polypeptides, thus chain-switching and 
product heterogeneity can be a problem in their production. In contrast, one of the advantages of Nbs is that all 
antigen activity is focussed on one independently folding binding unit which can be easily linked with other such 
binding  units29, 33, 37. We have shown that by simple linking together of two NB7-14 binding units we can enhance 
its potency over 1000-fold to and IC50 of 113 pM (Fig. 2). This also highlights a simple route to multi-paratopic 
nanobodies using Nbs belonging to different epitope groups which could be compared for mutational escape 
Figure 5.  HA structure showing nanobody epitope groups. Surface structure of hemagglutinin H7-HA 
[A(H7N9) A/Shanghai/02/2013, (PDB file 4LN6)] showing key residues for each epitope group using Pymol 
2.3.1 software. The structure shows HA1 domain (light green), HA2 domain (grey), and key residues for each 
epitope group, Gp1a (red), Gp1b/1c/1d (pink), Gp2 (yellow), Gp3 (blue) and Gp4 (brown). HA2 helix is shown 
in yellow with Gp5 epitopes residues highlighted in brown on the helix and numbering for the HA stem starts at 
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using yeast  display37. Multi-specific nanobodies to different epitopes on H7 could be stockpiled and bridge the 
gap until a vaccine is available during a pandemic emergency. Nanobodies have shown themselves to be capable 
of potent neutralisation of a range of different viruses including HIV-143,  RSV44,  rabies45 and influenza  virus29, 
38. Broad neutralising Nbs to pandemic influenza viruses could be expected to have considerable potential for 
therapy or prophylaxis and we have recently shown adeno-associated viral vector delivery is able to drive sus-
tained high level expression in situ and protection of mice from both pandemic H1N1 and highly pathogenic 
avian influenza  H5N146.
Human seasonal influenza A(H3N2) has been previously characterised as having 5 distinct antigenic sites 
(A, B, C, D, and E)47. The nanobody epitope Gp1 overlaps with antigenic sites E and A whereas epitope Gp4 
overlaps with antigenic site D (Fig. S5). In analysing the diversity of 324 H7N9 sequences (Table S1), we saw a 
high degree of conservation in the epitope footprint of Gp1 Nbs with D67, L70 and S135 being absolutely con-
served. The epitope group Gp1 is adjacent to the receptor binding site of HA and overlaps with antigenic site A, 
which is highly conserved amongst many H7 viruses, including strains of both Eurasian and North American 
Figure 6.  Correlation of epitope Gp2 specificity to natural sequence divergence. (a) Correlation of binding 
of NB7-03 (Gp3) and NB7-14 (Gp1a) to natural sequence divergence at K164. (b) ELISA of purified NB7-
14 (red) and NB7-03 (green) binding to inactivated whole virus antigen preparations from the following: A/
Guangdong/17SF003/2016 (H7N9); A/Anhui/01/2013 (H7N9) and A/Hong Kong/125/2017 (H7N9). (c) 
Confirmation of specificity of NB7-03 and NB7-14 to yeast cells displaying the HA1-K164E mutation.
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 lineages48, 49. Several human monoclonal antibodies which bind in this region from human donors exposed to 
H7N9 A/Shanghai/02/2013 and A/Anhui/01/2013  vaccines7, 19 have been shown to provide protection against 
H7N9 challenge, demonstrating the functional importance of this  epitope48, 50 and their potential as therapeutics. 
Nbs, such as NB7-14, which map to this region (Fig. S5) may also similarly have potential as a therapeutic or 
emergency prophylactic.
Nbs with H3/H7 cross-subtype reactivity and enhanced binding at low pH were located to the highly con-
served HA stem and belonged to epitope Gp5 (Fig. 4) (Table S1). Previous studies have described 66.5% sequence 
identity between H3 and H7 subtypes in the HA2 domain compared to 37% in the HA1 head  domain51. The stem 
region is crucial in mediating viral infection and undergoes a large structural re-arrangement in the acidified 
environment of the endosomal compartment. It has been proposed that H106 and adjacent residues compris-
ing M102 and E103 within the Gp5 epitope footprint function as a sensor for the enhanced protonation of HA 
at low  pH15. The increase in binding we see at low pH is consistent with Nbs showing preferential binding to 
the HA stem after it has gone through the specific pH dependent conformational change. Non-neutralising 
human antibodies with a pH sensitive binding have been described which correlated with increased phagocy-
tosis in vivo20. As Nbs NB37X-01 to 06 bind to a similar pH sensitive epitope they may be capable of similar 
mechanisms of viral neutralisation after appropriate reformatting as Fc-fusions to mediate interactions with 
phagocytic effector  cells46, 52, 53.
Nanobodies binding to epitope group 3 had a unique specificity which doesn’t overlap with any of the previ-
ously described antigenic sites from human immune responses to H7N9  influenza47 and may reflect a uniqueness 
to the immune response in alpacas that has not been shaped by prior exposure to IAV. This binding specificity 
could be correlated to natural sequence divergence at K164 between low (LP) and high pathogenicity (HP) H7N9 
influenza viruses. This is a further example of how yeast display and mutational scanning is able to correlate Nb 
specificity with natural sequence change, which, if applied predictively, could be used to assess the suitability 
of stockpiled nanobody reagents as new viruses  emerge28, 30. To our knowledge we have described the first Nbs 
capable of distinguishing (HP) A/Guangdong/17SF003/2016 (H7N9) strain from (LP) A/Hong Kong/125/2017 
(H7N9) and have been able to correlate this specificity to natural sequence divergence at K164 in the HA1 head 
domain. Since H7N9 presents in poultry with only mild symptoms, early warning signs of a pandemic may be 
extremely difficult to detect and the availability of specific Nbs formatted for rapid detection of this antigenic 
difference may be useful for influenza surveillance in the field using low cost  biosensors54.
In summary, we have isolated a panel of nanobodies to A(H7N9) which have been grouped on the basis of 
their epitopes and correlated this with their specificity and functional activity. They may be useful in monitoring 
the antigenic changes that occur in the HA of A(H7N9) during transmission in poultry, controlling the spread 
of virus in birds, or as emergency therapeutics in humans.
Methods
Reagents and influenza antigens. Whole influenza virus inactivated antigen standards (National 
Institute for Biological Standards and Control, NIBSC) used in this study were derived from strains: A/New 
York/107/2003 NIBRG-109 (H7N2) (08/362), A/Anhui/01/2013 NIBRG-268 (H7N9) (14/250), A/Mallard/
Netherlands/12/2000 NIBRG-60 (H7N3) (07/336), A/Uruguay/716/2007 NYMC X-175C (H3N2) (08/278), 
A/Guangdong/17SF003/2016 NIBRG-375 (H7N9) (18/196), A/Texas/50/2012 (H3N2) (13/116) and A/Hong-
Kong/125/2017 (H7N9) (IDVDV-RG58B, CBER-reference antigen #88),. Purified recombinant hemaggluti-
nins were full length HA0: A/Brisbane/10/2007 (H3N2), A/chicken/Netherlands/1/2003 (H7N7), A/Nether-
lands/219/2003 (H7N7), A/Shanghai/1/2013 (H7N9) (Protein Sciences) and HA1 (aa 26-344) A/chicken/
Netherlands/1/2003 (H7N7), A/Hong Kong/125/2017 (H7N9) (e-ENZYME). Reverse genetic influenza strain 
A/Anhui/01/2013 (H7N9) NIBRG-268 was used.
Construction and selection of phage and yeast displayed libraries. All methods performed on 
animals were carried out in accordance with relevant guidelines and regulations. All experimental protocols 
were reviewed and approved by the National Institute for Biological Standards (NIBSC) ethics committee and 
performed under United Kingdom Home Office License (PBF57622). A juvenile male alpaca was purchased 
through the Royal Veterinary College, Hertfordshire, UK. Primary immunisation and each subsequent boost 
was with 50 µg of purified H7-HA from A/Netherlands /219/2003 (Protein Sciences) and sample collection was 
performed as  in29. For antibody library construction approximately 10 ml samples of blood were collected from 
a immunised alpaca into heparinised tubes. Peripheral blood lymphocytes were purified using a ficol hypaque 
centrifugation procedure (Sigma-Aldrich) and RNA was extracted using a RiboPure RNA extraction kit (Nova-
gen) according to manufacturer’s instructions. First strand cDNA synthesis was performed using Superscript III 
reverse transcriptase (Invitrogen) and oligo-dT primer with 200 ng of total RNA per reaction. A phage displayed 
library was constructed in pNIBS-1 vector as described  previously29. This vector allows both phage display 
and production of soluble VHH nanobody fragments appended with a Histidine purification tag and a c-Myc 
epitope tag for detection of binding in ELISA.
Phage antibody library selections were performed essentially as  in29 using immunotubes (Thermo Fisher Sci-
entific) coated overnight at 4 °C with 1 ml of 10 µg/ml recombinant H7-HA (Protein Sciences) or whole influenza 
virus inactivated antigen standards (NIBSC) reconstituted in PBS. Bound phage antibodies were eluted by adding 
1 ml of 100 mM triethylamine followed by incubation for 10 min on a rotating platform at room temperature. 
The eluted phage were neutralised with 0.5 ml 1 M Tris-HCl pH 7.5. To amplify the selected phage for subsequent 
rounds of selection 1 ml of eluted phage were mixed with 5 ml of an Escherichia coli ER2738 (Agilent Technolo-
gies) culture grown to an  OD600 of 0.5 and 4 ml of 2 × TY media followed by incubation in a water bath at 37 °C 
for 30 min. This was then spread onto 22 cm bioassay dishes containing 2 × TY agar supplemented with 100 µg/
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ml (w/v) carbenicillin and 2% (w/v) glucose. Plates were grown overnight at 37 °C and harvested and the phage 
titres before and after selection were  determined29.
Yeast antibody libraries were generated using the same cDNA used for the construction of the phage libraries 
as template. Antibody genes were amplified with oligonucleotides: Alp_FR1_Sfi1_YRec (gggcggaggatctggtggcg-
gaggttctgcggcccagccggccATG GCA CAGKTGC AGC TCG TGG AGTCNGGNGG) and Alp_FR4back_Not1_YRec 
(tccaaacccaacaatgggtttgggattggcttaccagcggccgc TGA GGA GAC GGT GAC CTG ), where uppercase sequences 
anneal with antibody sequence extended lowercase sequences are included for subsequent yeast recombination 
and Sfi1/Not1 restriction sites are underlined. For each library, 20 µg of amplified PCR product was co-trans-
formed with 20 µg of Sfi1/Not1 digested pNIBS-5  vector28 into S. cerevisiae EBY100 competent cells. pNIBS-5 
is a yeast display vector which allows the display on yeast of proteins appended with a N-terminal SV5 epitope 
tag for detection. The final library size was determined through serial dilutions on selective plates as 2.25 × 107 
clones. Standard procedures and recipes for growth, induction, yeast cell labelling, media and buffer preparation 
were  used28. For yeast cell analysis and sorting we used 70 nM recombinant HA (eENZYME) followed by primary 
reagents monoclonal mouse anti-SV5 (Bio-Rad, MCA1360) and biotinylated monoclonal rabbit anti-His (Bethyl 
Laboratories, A190-114B) and by secondary reagents monoclonal goat anti-mouse IgG AlexaFluor488 (Thermo 
Fisher, Scientific, A11029) and streptavidin AlexaFluor647 (Thermo Fisher Scientific, S32357). For sorting ~ 108 
cells were labelled in the first round and 50,000 events were sorted decreasing to 5,000 events for subsequent 
rounds. Yeast plasmid DNA was purified from the final outputs and transformed into TG1 electro-competent 
Escherichia coli cells and 24 single bacterial colonies were sequenced to identify there VHH-CDR3 sequence. All 
yeast cell analysis and sorting was performed on BD Canto II or BDAria III flow cytometers (Becton Dickinson) 
respectively. Data was analysed using FlowJo 10.4  software28.
Nanobody expression and screening. Primary screening was carried out in a 96 well ELISA plate 
(Nunc) coated with recombinant HA at 1 µg/ml overnight in PBS at 4 °C29. Influenza virus antigen standards 
(National Institute for Biological Standards and Control, NIBSC) were reconstituted in 1 ml sterile water or PBS 
and then diluted 1/200 in 0.5 M bicarbonate buffer pH 9.6 prior to incubation overnight at 4 °C in a 96 well 
plate (Thermo Fisher Scientific). For primary screening soluble VHH antibodies were harvested from culture 
supernatants in a 96 well format. In short individual colonies from each round of selection were inoculated into 
100 µl of 2 × TY medium supplemented with 100 µg/ml (w/v) carbenicillin and 2% (w/v) glucose in a 96 well 
flat bottom plate (Corning) using sterile toothpick and grown overnight in a shaking incubator at 30 °C. From 
this master plate a new 96 well round bottom plate containing 100 µg/ml (w/v) carbenicillin and 0.1% (w/v) glu-
cose was grown at 37 °C for 6 h until OD 600 of approximately 0.9 was reached after which time 30 µl of 2 × TY 
supplemented with 100 µg /ml (w/v) carbenicillin plus 5 mM IPTG (1 mM final concentration) was added and 
incubation continued overnight. The plates were then centrifuged at 600 × g for two minutes and supernatants 
containing the soluble VHH nanobodies were harvested and tested in ELISA. After addition of 100 µl of nano-
body to individual wells and incubation for 1.5 h at room temperature, wells were washed with PBS and PBS-
tween 0.1% (v/v) before 100 µl of anti c-myc 9E10-HRP (1/1000 dilution) (Roche) in 2% (w/v) milk powder 
was added and binding detected at OD 450 nM using TMB after 15 min incubation at room temperature. In 
all ELISA’s a negative control nanobody with no known specificity was used. For their large-scale production, 
cloned VHH gene fragments were transformed into the non-suppressor Escherichia coli strain WK6, expressed 
and  purified28, 29. Nanobodies were purified from periplasmic preparations using immobilised metal chelate 
chromatography from the periplasmic fraction using Talon resin (Clontech). Eluted antibodies were dialysed 
against PBS using dialysis cassettes of molecular weight cut-off of 3 kDa (Thermo Fisher Scientific)29.
Nbs were converted into bivalent molecules using a (G4S)6 linker to fuse two Nb binding domains ‘head 
to tail’. Sequences of each nanobody unit were optimised to limit the percentage of GC content and to reduce 
internal homology within the construct. Constructs were assembled by PCR from overlapping oligonucleo-
tides, sub-cloned into pNIBS-1 and transformed into the Escherichia coli strain WK6. Bivalent nanobodies were 
expressed and purified as above.
Lentiviral pseudotype assays. Lentiviral pseudotypes were produced by transient co-transfection of 
HEK293T/17 cells using polyethylenimine. Plasmid p8.91 encodes the structural (gag, pol) genes and pCSFLW 
represents the genome incorporated into the pseudotypes bearing the firefly luciferase reporter. Influenza A 
hemagglutinin genes, in the expression plasmid pI.18 were also added to this mix alongside the Human Airway 
Trypsin (HAT) expression plasmid, pCAGGS-HAT, to allow for HA0 to HA1/2 maturation. The pseudotype 
based micro-neutralisation assay (pMN) was carried out in Nunc F96 microplates (Thermo Fisher Scientific). 
1:2 serial dilutions of nanobodies were performed across the 96-well plate in a total of 50  µl DMEM + 10% 
(w/v) fetal bovine serum and 1% (w/v) penicillin/streptomycin. HIV-1 derived lentiviral pseudotypes bearing 
influenza HA were then added to yield a relative luminescence unit (RLU) input of 1.5 × 106 per well, in a total 
volume of 50 µl. Plates were then incubated in a humidified incubator at 37 °C, 5%  CO2 for one hour, after which 
1.5 × 104 HEK293T/17 cells were added per well in a total volume of 50 µl. After 48 h, supernatants were removed 
and a 50:50 mix of PBS and Bright-Glo (Promega Corporation) was added to each well. Plates were incubated 
at room temperature for five minutes and then luminescence was read using a Glomax luminometer (Promega 
Corporation). Signals were normalised to cell and virus only controls, representing 100% and 0% neutralisation 
respectively.  IC50 values were calculated by non-linear regression using GraphPad Prism.
Analysis using surface plasmon resonance. For binding and affinity ranking against different full 
length recombinant HA0 and HA1 head domains we used single cycle kinetics on a Biacore T100 machine (GE 
Healthcare)39. In brief, HA was immobilised onto a Biacore CM5 chip in 10 mM sodium acetate pH 5.5 using an 
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amine coupling kit (GE Healthcare) to create surface densities of between 1000 and 3000 RU. A concentration 
series of purified nanobody were sequentially run over the different antigen surfaces ranging from 1 to 25 nM. A 
reference surface was subtracted prior to evaluation of the sensograms using the single cycle kinetics procedure 
of the Biacore T200 evaluation 3.1 software (GE Healthcare) in combination with a 1:1 fitting model.
Yeast display of hemagglutinin, error‑prone library construction and screening. Full length 
HA0, HA1 and HA2 (A/Netherlands/219/2003 (H7N7, D1-V508 mature protein numbering, HA1: D1-R323, 
HA2 G1-V185) respectively, were codon optimized for yeast expression and synthesised, including SfiI-NotI 
restriction sites (Integrated DNA Technologies), cloned into the yeast display vector pNIBS-5 and transformed 
into S. cerevisiae EBY10028. Standard procedures and recipes for growth, induction, yeast cell labelling, media 
and buffer preparation were used. Staining with purified Nbs was performed by incubating cells with 100 nM of 
Nbs followed by monoclonal mouse anti-SV5 (Bio-Rad, MCA1360) and polyclonal chicken anti-cMyc (Bethyl 
Laboratories, A190-203A) followed by secondary reagents monoclonal goat anti-mouse IgG AlexaFluor488 
(Thermo Fisher Scientific, A11029) and goat anti-chicken IgG AlexaFluor647 (Jackson ImmunoResearch, 103-
605-155). Anti-influenza control H3 and H7 specific antibodies MIA-H7-334 and MIA-H3-501 were used (eEn-
zyme). Labelled yeast cells were analysed on BD Canto II or BDAria III flow cytometers.
Error prone PCR amplification of the HA gene was carried out using a GeneMorph mutagenesis kit according 
to manufacturer’s instruction (Agilent Technologies) and 20 µg of mutated PCR product was co-transformed with 
20 µg of Sfi1/Not1 digested pNIBS-5 yeast display  vector28 into S. cerevisiae EBY100 competent cells (Invitrogen). 
The final library size was determined through serial dilutions on selective plates, and yeast plasmid minipreps of 
the library was transformed into TG1 electro-competent Escherichia coli cells (Agilent Technologies) for single 
colony sequencing. Individual colonies were picked and sequenced to assess mutation frequency. The yeast library 
was grown in selective medium for induction of HA display.  108 cells were co-stained with 100 nM Nb, followed 
by anti-SV5/anti-cMyc antibodies to detect Nb binding and HA display using fluorescent secondary reagents as 
described above. Flow cytometric cell sorting was performed using BDAria III. For the first round of a sorting 
a gate was chosen to sort cells displaying HA (by virtue of anti-SV5 signal) but absence of nanobody binding 
(lower right quadrant of a FACS dot plot). A second round was performed using the same sorting conditions. A 
third round of ‘positive’ sorting was done using 200 nM of a non-competing nanobody of NB37X-01 for epitope 
mapping of HA1 specific nanobodies (NB7-14, NB7-08, NB7-15, NB7-03, NB7-05) and NB7-14 for epitope map-
ping of the stem specific nanobodies (NB37X-01, NB37X-05). Yeast plasmid DNA was purified from the final 
outputs and transformed into TG1 electro-competent Escherichia coli cells and single bacterial colonies were 
sequenced. Sequence reads were assembled and aligned to the wild-type HA0 or HA1 genes to identify candidate 
mutations. Yeast clones with defined mutations were separately labelled for HA display and Nb binding. The 
Nb binding mean fluorescence intensity (MFI) of each Nb-mutant HA pair was divided by the MFI value of the 
wild-type H7-HA interaction, and the resulting ratio normalised to percentage values. Binding was categorized 
as follows, ≤ 15% no binding, between 15 and 40% intermediate binding and ≥ 40% strong binding (green).
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